TY - JOUR
T1 - Basic and clinical studies of tazobactam/piperacillin in the urological field
AU - Hayashi, Toshihide
AU - Watanabe, Toyohiko
AU - Takenaka, Tadasu
AU - Sakuramoto, Kouji
AU - Hata, Kazuhiro
AU - Ono, Noriaki
AU - Kumon, Hiromi
AU - Ohmori, Hiroyuki
AU - Kondo, Katsuyoshi
AU - Katayama, Yasuhiro
AU - Akaeda, Teruaki
AU - Hayata, Shunji
AU - Asahi, Toshihiko
AU - Yamada, Daisuke
PY - 1994/1/1
Y1 - 1994/1/1
N2 - We studied the antibacterial activity and clinical efficacy of a new combined drug, tazobactam/piperacillin (TAZ/PIPC), prepared at a ratio of 1: 4, in the urological field. 1) Antibacterial activity: We measured the MICs of TAZ/PIPC against clinical isolates (206 strains of 14 species) from urinary tract infections, and compared them with those of piperacillin (PIPC), sulbactam/cefoperazone (SBT/CPZ), latamoxef (LMOX), and ceftazidime (CAZ). Against gram-positive bacteria, the antibacterial activity of TAZ/PIPC was almost equal to that of PIPC, but was superior to that of other control drugs, whereas against Staphylococcus epidermidis, the activity of TAZ/PIPC was inferior to that of SBT/CPZ. Against gram-negative bacteria the antibacterial activity of TAZ/PIPC was almost equal to that of SBT/CPZ and equal to or twice that of PIPC but inferior to that of LMOX and CAZ. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 73.3%(22/30) for chronic complicated UTI. Bacteriologically, 38 of 48 strains (79.2%) were eradicated. 3) Side effects: No subjective side effects were observed in this investigation. Liver dysfunction in three cases and eosinophilia in one case were observed, but these were not severe.
AB - We studied the antibacterial activity and clinical efficacy of a new combined drug, tazobactam/piperacillin (TAZ/PIPC), prepared at a ratio of 1: 4, in the urological field. 1) Antibacterial activity: We measured the MICs of TAZ/PIPC against clinical isolates (206 strains of 14 species) from urinary tract infections, and compared them with those of piperacillin (PIPC), sulbactam/cefoperazone (SBT/CPZ), latamoxef (LMOX), and ceftazidime (CAZ). Against gram-positive bacteria, the antibacterial activity of TAZ/PIPC was almost equal to that of PIPC, but was superior to that of other control drugs, whereas against Staphylococcus epidermidis, the activity of TAZ/PIPC was inferior to that of SBT/CPZ. Against gram-negative bacteria the antibacterial activity of TAZ/PIPC was almost equal to that of SBT/CPZ and equal to or twice that of PIPC but inferior to that of LMOX and CAZ. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 73.3%(22/30) for chronic complicated UTI. Bacteriologically, 38 of 48 strains (79.2%) were eradicated. 3) Side effects: No subjective side effects were observed in this investigation. Liver dysfunction in three cases and eosinophilia in one case were observed, but these were not severe.
UR - http://www.scopus.com/inward/record.url?scp=0028007504&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028007504&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.42.Supplement2_541
DO - 10.11250/chemotherapy1953.42.Supplement2_541
M3 - Article
AN - SCOPUS:0028007504
SN - 0009-3165
VL - 42
SP - 541
EP - 552
JO - Chemotherapy
JF - Chemotherapy
ER -
